Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Astellas Pharma

Tracked across 9 events · 168 articles · First seen Apr 20, 2026 · Last active Sep 14, 2026

Sentiment
3
Attention
6
Events
9
Relationships
2
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
6 40
Domestic
On August 31, 2026, President Donald Trump announced voluntary drug pricing agreements with nine pharmaceutical companies: Alcon, Astellas Pharma, BeOne Medicines, BridgeBio Pharma, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB. These companies agreed…
Impact: Astellas signed a drug pricing deal, extending MFN pricing to United States — Medicaid. This aligns with its earlier participation and may impact U.S. pricing but secures tariff exemptions.
Aug 18, 2026 · 37 articles
6 10
Regulatory
Impact: Astellas Pharma is one of the few mid-sized drug companies that confirmed its application to the United States — Medicaid pilot program, viewing it as a constructive path forward in a complex policy environment.
Apr 20, 2026 · 6 articles
4 -20
Regulatory
Impact: Astellas Pharma is the manufacturer of the reference listed drug Xtandi Tablets, to which Lupin (company)'s Enzalutamide Tablets were found bioequivalent. This approval could introduce competition for Astellas Pharma's product.
Jun 26, 2026 · 16 articles
4 -40
Business
Impact: Astellas Pharma's stock declined, showing a negative performance.
May 21, 2026 · 40 articles
4 30
Business
Impact: Astellas Pharma gained almost 5% on one day, reflecting positive sentiment.
Jul 24, 2026 · 37 articles
4 0
Business
Impact: Astellas Pharma has licensed MiNK Therapeutics' STAC-BBB platform for neurological targets, indicating a past business relationship that could be affected by Sangamo's strategic review.
Jun 08, 2026 · 7 articles
3 5
Tech
Impact: Provided funding via Astellas Foundation.
Jun 24, 2026 · 7 articles
4 0
Business
Impact: Astellas is mentioned as part of Royalty Pharma's portfolio but is unaffected by this event.
Sep 04, 2026 · 12 articles
1 0
Tech
Basilea Pharmaceutica announced that its Japanese partner Asahi Kasei started a Phase 2 clinical study of the antifungal Cresemba (isavuconazole) in Japan for pediatric patients at risk of deep mycoses. The multicenter, open-label, non-controlled study…
Impact: Astellas is referenced as the source of the US prescribing information for Cresemba, indicating its role in the product's US commercialization.
Sep 14, 2026 · 6 articles
60 Astellas Pharma donated active pharmaceutical ingredients United StatesTrump announces nine new...
ERGEN INTELLIGENCE
Track Astellas Pharma live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.